title: Modeling and Simulation for Estimating the Influence of Renal Dysfunction on the Hypouricemic Effect of Febuxostat in Hyperuricemic Patients Due to Overproduction or Underexcretion of Uric Acid.
abstract: Whether renal dysfunction influences the hypouricemic effect of febuxostat, a xanthine oxidase (XO) inhibitor, in patients with hyperuricemia due to overproduction or underexcretion of uric acid (UA) remains unclear. We aimed to address this question with a modeling and simulation approach. The pharmacokinetics (PK) of febuxostat were analyzed using data from the literature. A kinetic model of UA was retrieved from a previous human study. Renal UA clearance was estimated as a function of creatinine clearance (CLcr) but non-renal UA clearance was assumed constant. A reversible inhibition model for bovine XO was adopted. Integrating these kinetic formulas, we developed a PK-pharmacodynamic (PK-PD) model for estimating the time course of the hypouricemic effect of febuxostat as a function of baseline UA level, febuxostat dose, treatment duration, body weight, and CLcr. Using the Monte Carlo simulation method, we examined the performance of the model by comparing predicted UA levels with those reported in the literature. We also modified the models for application to hyperuricemia due to UA overproduction or underexcretion. Thirty-nine data sets comprising 735 volunteers or patients were retrieved from the literature. A good correlation was observed between the hypouricemic effects of febuxostat estimated by our PK-PD model and those reported in the articles (observed) (r=0.89, p<0.001). The hypouricemic effect was estimated to be augmented in patients with renal dysfunction irrespective of the etiology of hyperuricemia. While validation in clinical studies is needed, the modeling and simulation approach may be useful for individualizing febuxostat doses in patients with various clinical characteristics.
authors.affiliation: Department of Pharmacy, Tokyo Women's Medical University Hospital.
authors.forename: Toshinori
authors.initials: T
authors.lastname: Hirai
authors.forename: Toshimi
authors.initials: T
authors.lastname: Kimura
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Echizen
mesh_terms: D003198:Computer Simulation; D000069465:Febuxostat / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D006074:Gout Suppressants / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D033461:Hyperuricemia / Q000097:blood* / Q000188:drug therapy; D008954:Models, Biological; D051436:Renal Insufficiency, Chronic / Q000097:blood*; D014527:Uric Acid / Q000097:blood*; D019820:Xanthine / Q000097:blood; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors
chemical_list: D006074:Gout Suppressants; D000069465:Febuxostat; D019820:Xanthine; D014527:Uric Acid; D014969:Xanthine Oxidase